Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12850591 | 0.93 | CASR (0.54) | CASRSIRT1 | |
| SCHEMBL12614170 | 0.92 | CASR (0.72) | CASR | |
| Hydrochloric Acid SCHEMBL15410567 | 0.91 | CASR (0.73) | CASR | |
| SCHEMBL12695860 | 0.86 | CASR (0.74) | CASR | |
| SCHEMBL15411491 | 0.85 | SIRT1 (0.54) | CASRSIRT1 | |
| SCHEMBL12850548 | 0.85 | CASR (0.61) | CASR | |
| SCHEMBL12850514 | 0.85 | CASR (0.83) | CASR | |
| SCHEMBL12850708 | 0.85 | SIRT1 (0.56) | CASRSIRT1 | |
| Hydrochloric Acid SCHEMBL15411311 | 0.85 | CASR (0.62) | CASR | |
| Hydrochloric Acid SCHEMBL15411909 | 0.84 | CASR (0.84) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2686306-B1 | BENZO[B][1,4]OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2017-01-04 | — | — | EP | claimed |
| US-9464063-B2 | Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-10-11 | — | — | US | claimed |
| US-20140018358-A1 | BENZO [B] [1,4] OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2014-01-16 | — | — | US | claimed |
| EP-2686306-B1 | BENZO[B][1,4]OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2017-01-04 | — | — | EP | disclosed |
| EP-2686306-B1 | BENZO[B][1,4]OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2017-01-04 | — | — | EP | disclosed |
| US-9464063-B2 | Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-9464063-B2 | Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-9464063-B2 | Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-20140018358-A1 | BENZO [B] [1,4] OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2014-01-16 | — | — | US | disclosed |
| US-20140018358-A1 | BENZO [B] [1,4] OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2014-01-16 | — | — | US | disclosed |
| US-20140018358-A1 | BENZO [B] [1,4] OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2014-01-16 | — | — | US | disclosed |
| WO-2012127388-A1 | BENZO [B] [1, 4] OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018358-A1 | BENZO [B] [1,4] OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS | CASR, RYR1, RYR2 | CASR 1/4885SIRT1 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.